retatrutide clinical study ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Retatrutide Phase 3: TRIUMPH Program
Description
These trends are mostly driven by oncology and anti-diabetics, including significant growth in GLP-1 medications such as Ozempic. Kaiser Foundation Health Plan of Washington (Washington) MVP has seen rapidly increasing utilization of Glucagon-like peptide-1 (GLP-1) drugs throughout 2024
Wang F, Knutson K, Alcaino C
These medications mimic the action of a natural hormone called glucagon-like peptide-1
K., Mueller-Gomez, J
